Pembrolizumab-Associated Cutaneous and Pulmonary Sarcoidosis in Non-Small Cell Lung Cancer Treatment

Immune checkpoint inhibitor (ICI) therapy has reshaped the treatment landscape in many cancers including non-small cell lung cancer (NSCLC). ICI-therapy can lead to a diverse array of immune-related adverse effects (irAEs), and prompt recognition and management are key to successful treatment. With wide-spread use of ICI therapy in clinical practice, rare irAEs are being increasingly recognized. This report documents a patient with advanced NSCLC who developed pembrolizumab-associated sarcoidosis with multiorgan involvement. Multidisciplinary management led to timely diagnosis and treatment, leading to improvement in symptoms. This case raises awareness of sarcoidosis as a rare side effect of pembrolizumab. (C) 2022 Elsevier Inc. All rights reserved.

Automated summary

Immune checkpoint inhibitor therapy has revolutionized the treatment approach for various cancers, including non-small cell lung cancer. However, this therapy can give rise to a wide range of immune-related adverse effects, necessitating prompt identification and management. As the use of immune checkpoint inhibitors becomes more prevalent, rare immune-related adverse effects are increasingly being recognized. This case report presents a patient with advanced non-small cell lung cancer who developed pembrolizumab-associated sarcoidosis involving multiple organs. A multidisciplinary approach to management led to timely diagnosis and treatment, resulting in symptom improvement. This case raises awareness about the rare side effect of sarcoidosis associated with pembrolizumab.